Navigation Links
Study Confirms Third Trimester Amniotic Fluid a Reliable Source of Stem Cells for Regenerative Medicine and Stem Cell Banking
Date:2/16/2011

MEDFORD, Mass., Feb. 16, 2011 /PRNewswire/ -- In a study that was presented at the Society for Maternal-Fetal Medicine's annual meeting in San Francisco, Biocell Center, the leader in amniotic fluid banking, together with a group of collaborators, confirmed that amniotic fluid collected during the third trimester of pregnancy is a reliable source of stem cells for regenerative medicine and stem cell banking.

Amniotic fluid has emerged as one of the most attractive sources of mesenchymal stem cells with broad utility for stem cell therapy development. The stem cells contained in amniotic fluid are multifunctional and can grow into many different organs and tissues. Research shows that these stem cells could be used to repair cartilage in the knee, heal wounds or grow heart valves. There are 160 human clinical trials around the world evaluating cells similar to the ones found in amniotic fluid, and researchers predict innovations to continue.

"Amniotic fluid banking is the latest advance in stem cell preservation. Research with these stem cells is leading to significant medical discoveries, and the only way to take advantage is to plan ahead and preserve now," says Dr. Kate Torchilin, PhD, CEO of Biocell Center. "Additionally, a little bit of fluid can be easily collected during prenatal tests throughout pregnancy."

The study confirms that amniotic fluid collected during the third trimester contains mesenchymal stem cells that are similar to younger amniotic fluid cells collected earlier in pregnancy, and potentially enables many more pregnant women to save amniotic fluid.

Amniotic fluid preservation has been widely available in Europe for years, and is rapidly gaining traction in the US. Families banking amniotic fluid now can give their child many options for the future.

"I recommend that moms undergoing certain prenatal tests, such as amniocentesis, in the second or third trimester, discuss saving this fluid with their doctor as soon as they know they will be having an amnio," says Dr. Lucy Bayer, the chief Maternal Fetal Medicine Doctor at St. Elizabeth Hospital and one of the investigators for the study. "Additionally, I am very excited about these findings, as they affirm amniotic fluid as an excellent source of cells for tissue regeneration."

The study comes out just 2 weeks after the first national Amniotic Fluid Awareness Day that educated expecting families about the benefits of amniotic fluid beyond pregnancy.

For more information about Amniotic Fluid Awareness day or amniotic fluid banking, visit http://www.biocellcenter.com or call 1-866-246-2720.

About Amniotic Fluid Stem CellsAmniotic fluid contains fetal cells that are normally shed during growth, and other chemicals and substances. Amniotic fluid can provide important information about baby's health before birth.

About Biocell CenterBiocell Center, the leader in amniotic fluid preservation was founded by internationally renowned doctors and scientists with decades of experience in prenatal testing and stem cells. Biocell Center offers amniotic fluid cell cryopreservation services worldwide.MEDIA CONTACTS:GCI HealthAndrea FassacesiaPh: (212) 798-9942This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE Biocell Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
2. New test to study proteins involved in neurodegenerative diseases
3. A new model for studying Parkinsons
4. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
5. Columbia University researchers use nanoscale transistors to study single-molecule interactions
6. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
7. New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries
8. Professor Dennis Lo Trisomy 21 Clinical Validation Study Published in British Medical Journal
9. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
11. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Eurofins announces the appointment of Sean Murray ... Scientific Inc. (ESI). Mr. Murray will bring valuable ... entrepreneurial experience in leading international business teams. As the National Division ... to uphold Eurofins, status as the global leader in bio-analytical testing ... , , ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), The Molecular ... with the launch of the SureSeq myPanel™ NGS Custom FH ... familial hypercholesterolemia (FH). The panel delivers single nucleotide variation (SNV) ... panel and allows customisation by ,mix and match, of fully-optimised ... LDLR , P C SK9 , ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, uBiome, ... is one of just six company finalists in the Health & Medicine category. ... companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, and ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
Breaking Biology Technology:
(Date:12/7/2016)... 7, 2016 BioCatch , the global leader ... patent portfolio, which grew to over 40 granted and pending patents. ... , , ... entitled " System, Device, and Method Estimating Force Applied to ... makers to forego costly hardware components needed to estimate the force and ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
Breaking Biology News(10 mins):